Munity+
Munity+, licence 80062996: active licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Other names
- Garlimune, Odorless 2% Allicin Oil with Vit. E
- Licence holder
- Munity+ Canada Inc.
- NPN or DIN-HM
- 80062996
- Status
- Active licence
- Licence date
- 27 July 2015
- Revision date
- Not provided
- Form
- Capsule, molle
- Route of administration
- Orale
- Application type
- Officinale
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Allium sativum Source : Bulbe | 12.0 milligramme | Not calculated |
| Vitamine E Source : Acétate de d-alpha tocophéryle | 1.0 milligramme | 1,000 µg |
| Vitamine E Source : Helianthus annuus - Graine | 1.0 milligramme | 1,000 µg |
| Vitamine E Source : Glycine max - Graine | 1.0 milligramme | 1,000 µg |
Non-medicinal ingredients
Huile de tournesol, Gélatine, NA, Glycérine
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 1.0 Capsule | 1.0 Tous les jours |
Uses authorised in Canada
Supports a healthy immune system and helps with upper respiratory tract infections. Help in reducing elevated cholesterol levels.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Effets indésirables connus
Allergy has been known to occur; in which case discontinue use.
- Précautions et mises en garde
Pregnant women should consult a health care practitioner prior to use.
- Contre-indications
Do not take if you are using blood thinners or protease inhibitors.
Source
Official Health Canada record, licence 80062996
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.